These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 21802914)
1. Adherence to treatment guidelines in stage II/III rectal cancer in Alberta, Canada. Eldin NS; Yasui Y; Scarfe A; Winget M Clin Oncol (R Coll Radiol); 2012 Feb; 24(1):e9-17. PubMed ID: 21802914 [TBL] [Abstract][Full Text] [Related]
2. Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan, and Manitoba in 2004. Cree M; Tonita J; Turner D; Nugent Z; Alvi R; Barss R; King C; Winget M Clin Colorectal Cancer; 2009 Jul; 8(3):141-5. PubMed ID: 19632928 [TBL] [Abstract][Full Text] [Related]
3. Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline-recommended treatment. Winget M; Hossain S; Yasui Y; Scarfe A Cancer; 2010 Oct; 116(20):4849-56. PubMed ID: 20578180 [TBL] [Abstract][Full Text] [Related]
4. Referral rate to oncologists and its variation by hospital for colorectal cancer patients. Kreiter E; Yasui Y; de Gara C; White J; Winget M Ann Surg Oncol; 2012 Mar; 19(3):714-21. PubMed ID: 21922337 [TBL] [Abstract][Full Text] [Related]
5. Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, Canada. Lima IS; Yasui Y; Scarfe A; Winget M Cancer; 2011 Aug; 117(16):3833-40. PubMed ID: 21319156 [TBL] [Abstract][Full Text] [Related]
6. Uptake and tolerance of adjuvant chemotherapy in early stage NSCLC patients in Alberta, Canada. Winget M; Fleming J; Li X; Gao Z; Butts C Lung Cancer; 2011 Apr; 72(1):52-8. PubMed ID: 20708293 [TBL] [Abstract][Full Text] [Related]
7. Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Cronin DP; Harlan LC; Potosky AL; Clegg LX; Stevens JL; Mooney MM Am J Gastroenterol; 2006 Oct; 101(10):2308-18. PubMed ID: 17032196 [TBL] [Abstract][Full Text] [Related]
8. [Histologic response after neoadjuvant therapy in rectal adenocarcinoma: own experience and review of the literature]. Mátrai Z; Lövey J; Hitre E; Orosz Z; Gödény M; Péley G; Sulyok Z; Rényi Vámos F; Farkas E; Köves I Orv Hetil; 2006 Oct; 147(42):2011-20. PubMed ID: 17165600 [TBL] [Abstract][Full Text] [Related]
9. Preoperative or postoperative therapy for stage II or III rectal cancer: an updated practice guideline. Wong RK; Berry S; Spithoff K; Simunovic M; Chan K; Agboola O; Dingle B; Clin Oncol (R Coll Radiol); 2010 May; 22(4):265-71. PubMed ID: 20398849 [TBL] [Abstract][Full Text] [Related]
10. Patient profile and treatment outcome of rectal cancer patients treated with multimodality therapy at a regional cancer center. Deo S; Kumar S; Shukla NK; Kar M; Mohanti BK; Sharma A; Raina V; Rath GK Indian J Cancer; 2004; 41(3):120-4. PubMed ID: 15472410 [TBL] [Abstract][Full Text] [Related]
11. Patterns of chemotherapy use for women with ovarian cancer: a population-based study. Cress RD; O'Malley CD; Leiserowitz GS; Campleman SL J Clin Oncol; 2003 Apr; 21(8):1530-5. PubMed ID: 12697877 [TBL] [Abstract][Full Text] [Related]
12. Outcomes of multimodality therapies for patients with stage II or III rectal cancer in California, 1994-2009. Cho MM; Morgan JW; Knutsen R; Oda K; Shavlik D; Knutsen S; Kazanjian K Dis Colon Rectum; 2013 Dec; 56(12):1357-65. PubMed ID: 24201389 [TBL] [Abstract][Full Text] [Related]
13. Variability in the quality of rectal cancer care in public hospitals in Catalonia (Spain): clinical audit as a basis for action. Manchon-Walsh P; Borras JM; Espinas JA; Aliste L; Eur J Surg Oncol; 2011 Apr; 37(4):325-33. PubMed ID: 21296543 [TBL] [Abstract][Full Text] [Related]
14. Elderly patients with colorectal cancer are oncologically undertreated. Bojer AS; Roikjær O Eur J Surg Oncol; 2015 Mar; 41(3):421-5. PubMed ID: 25592663 [TBL] [Abstract][Full Text] [Related]
15. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523 [TBL] [Abstract][Full Text] [Related]
17. Effect of adjuvant radiotherapy on local recurrence in stage II rectal cancer. Park IJ; Kim HC; Yu CS; Kim TW; Jang SJ; Kim JC Ann Surg Oncol; 2008 Feb; 15(2):519-25. PubMed ID: 17960464 [TBL] [Abstract][Full Text] [Related]
18. The surgeon as prognostic factor for local recurrence and survival in the anal sphincter preservation for mid-rectal cancer. Luna-Pérez P; Reyna Huelga A; Labastida Almendaro S; Rodríguez-Coria DF; González Macouzet J; Delgado Gallardo S Rev Invest Clin; 1999; 51(4):205-13. PubMed ID: 10546501 [TBL] [Abstract][Full Text] [Related]
19. Predictors of surgery and consult with an oncologist for adjuvant chemotherapy in early stage NSCLC patients in Alberta, Canada. Winget M; Stanger J; Gao Z; Butts C J Thorac Oncol; 2009 May; 4(5):629-34. PubMed ID: 19276835 [TBL] [Abstract][Full Text] [Related]
20. Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. Pucciarelli S; Capirci C; Emanuele U; Toppan P; Friso ML; Pennelli GM; Crepaldi G; Pasetto L; Nitti D; Lise M Ann Surg Oncol; 2005 Feb; 12(2):111-6. PubMed ID: 15827790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]